Velocity Clinical Research Union

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• COPD4 trials
• Long COVID and ME/CFS1 trial
• Obesity1 trial
• Postural tachycardia syndrome (POTS)1 trial
• Type 2 diabetes1 trial

Phase

• Phase 25 trials
• Phase 31 trial
• Phase 41 trial

Status

• Active, not recruiting3 trials
• Completed2 trials
• Recruiting1 trial
• Terminated1 trial

Lead sponsor

• Altesa Biosciences, Inc.1 trial
• CSL Behring1 trial
• Currax Pharmaceuticals1 trial
• Novo Nordisk A/S1 trial
• Uniquity One (UNI)1 trial
• and 2 more

Running trials

• Recruiting

  Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD

  NCT07610395· Phase 2· Altesa Biosciences, Inc.· Source

  Contact: Velocity Clinical Research - Union

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD

  NCT06981078· Phase 2· Upstream Bio Inc.· Source

• Active, not recruiting

  A Study to Evaluate Solrikitug in Participants With COPD (ZION)

  NCT06496620· Phase 2· Uniquity One (UNI)· Source

• Active, not recruiting

  Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

  NCT06098079· Phase 4· Currax Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD1 recruiting

Closed trials

• Terminated

  Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS

  NCT06524739· Phase 3· CSL Behring· Source

• Completed

  A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

  NCT06545500· Phase 2· Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA· Source

• Completed

  A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

  NCT05486065· Phase 2· Novo Nordisk A/S· Source